3 February 2022 - Public comment period now open until 3 March 2022; requests to make oral comment during public meeting also being accepted,

The Institute for Clinical and Economic Review today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of the following treatments for COVID-19:

• Sotrovimab (GlaxoSmithKline and Vir Biotechnology)
• Molnupiravir (Merck/MSD)
• Nirmatrelvir and ritonavir (Paxlovid, Pfizer)
• Fluvoxamine (Investigator initiated)

Read ICER Announcement